Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort studyNarendranath Epperla, Reem Karmali, Lei Feng et al.|Journal of Hematology & Oncology|2023Cited by 52
Peri–CAR-T practice patterns and survival predictors for all CAR-T patients and post–CAR-T failure in aggressive B-NHLJoanna Zurko, Reem Karmali, Kevin A. David et al.|Blood Advances|2022Cited by 50
Exploiting the fibroblast growth factor receptor-1 vulnerability to therapeutically restrict the MYC-EZH2-CDKN1C axis-driven proliferation in Mantle cell lymphomaAnuvrat Sircar, Lalit Sehgal, Satishkumar Singh et al.|Leukemia|2023Cited by 13
Loncastuximab in High-Risk and Heavily-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Real World Analysis from 21 US CentersEmily C. Ayers, Narendranath Epperla, Viktoriya Zelikson et al.|Blood|2023Cited by 10
Loncastuximab in high-risk and heavily pretreated relapsed / refractory diffuse large B-cell lymphoma: a real-world analysis from 21 US centersViktoriya Zelikson, Emily C. Ayers, Ashwath Gurumurthi et al.|Haematologica|2024Cited by 6